The role of IDO in brain tumor immunotherapy

Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors

(2014) D. A. Wainwright et al.   CLINICAL CANCER RESEARCH

The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma

(2014) Minghui Li et al.   Journal for ImmunoTherapy of Cancer

Gliomas Promote Immunosuppression through Induction of B7-H1 Expression in Tumor-Associated Macrophages

(2013) O. Bloch et al.   CLINICAL CANCER RESEARCH

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Expression of Indoleamine 2,3-Dioxygenase and Correlation With Pathological Malignancy in Gliomas

(2013) Kentaro Mitsuka et al.   NEUROSURGERY

Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2

(2012) Supun M. Bakmiwewa et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation

(2012) Feng Qian et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival

(2012) D. A. Wainwright et al.   CLINICAL CANCER RESEARCH

The Aryl Hydrocarbon Receptor Complex and the Control of Gene Expression

(2012) Timothy V. Beischlag et al.   CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION

Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase

(2012) L. Pilotte et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan

(2012) Richard Metz et al.   OncoImmunology

Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors

(2011) David Meininger et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Cooperativity within and among Pten, p53, and Rb Pathways Induces High-Grade Astrocytoma in Adult Brain

(2011) Lionel M.L. Chow et al.   CANCER CELL

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

(2011) Christiane A. Opitz et al.   NATURE

Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells

(2011) Maria T Pallotta et al.   NATURE IMMUNOLOGY

Biochemical characteristics and inhibitor selectivity of mouse indoleamine 2,3-dioxygenase-2

(2010) Christopher Jonathan Daraius Austin et al.   AMINO ACIDS

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

(2010) X. Liu et al.   BLOOD

1-l-methyltryptophan is a more effective inhibitor of vertebrate IDO2 enzymes than 1-d-methyltryptophan

(2010) Hajime J. Yuasa et al.   COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR BIOLOGY

Foxo Transcription Factors Control Regulatory T Cell Development and Function

(2010) Yann M. Kerdiles et al.   IMMUNITY

An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells

(2010) J. D. Mezrich et al.   JOURNAL OF IMMUNOLOGY

Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism

(2010) N. T. Nguyen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells

(2009) D. J. Chung et al.   BLOOD

Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases

(2009) Hajime J. Yuasa et al.   COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR BIOLOGY

Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice

(2009) Masaaki Kanai et al.   Molecular Brain

CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer

(2008) Yoshiki Mizukami et al.   INTERNATIONAL JOURNAL OF CANCER

SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis

(2008) C. Orabona et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA